Pipeline
We are developing therapies to counteract the devastating progression of neurodegenerative diseases.
ABC = Alector Brain Carrier
Ab = Antibody
Aβ = Amyloid Beta
AD = Alzheimer’s Disease
α-Syn = Alpha-Synuclein
ERT = Enzyme Replacement Therapy
GD = Gaucher Disease
LBD = Lewy Body Dementia
NLRP3 = NOD-, LRR-, and pyrin domain-containing protein 3
PD = Parkinson’s Disease
siRNA = Small Interference RNA
UD = Undisclosed
Close
AL037/AL137-ABC
Target
Aβ-Abs
Indication
AD
Development Stage
Preclinical
AL037/AL137-ABC is a proprietary anti-amyloid beta (Aβ) antibody paired with the company’s ABC for the treatment of AD. It is designed to remove brain amyloid plaques, with the potential to reduce the risk of amyloid-related imaging abnormalities (ARIA) and enable subcutaneous delivery. It targets a validated epitope specific to brain amyloid plaques, combined with an optimized antibody constant region to enhance phagocytosis of Aβ plaques. By leveraging ABC technology, AL037/AL137-ABC aims to clear Aβ efficiently, thereby reducing plaque accumulation and slowing disease progression while minimizing ARIA.
Close
AL064/AL164-ABC
Target
Tau-siRNA
Indication
AD and other tauopathies
Development Stage
Preclinical
AL064/AL164 targets tau pathology in Alzheimer’s disease. It combines an anti-tau siRNA, which inhibits the synthesis of tau mRNA and protein, with the Alector Brain Carrier to potentially slow disease progression.
Close
AL050-ABC
Target
GCase-ERT
Indication
PD, GD, LBD
Development Stage
Preclinical
AL050 is a GCase enzyme replacement therapy paired with the company’s proprietary ABC for GBA gene mutation carriers with Parkinson’s disease and Lewy body dementia. In these patients, mutations in the GBA gene lead to deficient GCase activity. AL050 uses Alector-engineered GCase, which has been designed to have a longer half-life and to break down glucocerebroside, a lipid that accumulates in neurons and contributes to neurodegeneration. This mechanism aims to reduce cellular dysfunction and slow disease progression.
Close
ADP062-ABC
Target
α-Syn-siRNA
Indication
PD
Development Stage
ADP062-ABC targets α-synuclein pathology in Parkinson’s disease. It combines an anti-α-synuclein siRNA, which inhibits the synthesis of α-synuclein mRNA and protein, with the Alector Brain Carrier to potentially slow disease progression.
Close
ADP065-ABC
Target
NLRP3-siRNA
Indication
AD, PD
Development Stage
ADP065-ABC targets NLRP3-driven neuroinflammation in Alzheimer’s disease and Parkinson’s disease. It combines an anti-NLRP3 siRNA, which inhibits the synthesis of NLRP3 mRNA and protein, with the Alector Brain Carrier to potentially slow disease progression.